Asset Details
Do you wish to reserve the book?
Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis
Do you wish to request the book?
Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis
2019
Overview
Trimethylamine N-oxide (TMAO), a gut microbe-derived metabolite of dietary choline and other trimethylamine-containing nutrients, has been linked to increased cardiovascular disease risk. It is unknown whether TMAO plays a role in the development of cardiac hypertrophy. Transverse aortic constriction (TAC) was performed to induce cardiac hypertrophy in Sprague-Dawley (SD) rats. We observed that TMAO levels were significantly elevated in SD rats after 6 weeks of TAC, suggesting the potential role of TMAO in regulating cardiac hypertrophy. In cultured cardiomyocytes, TMAO treatment stimulated cardiac hypertrophy, as indicated by increased cell area of cardiomyocytes and expression of hypertrophic markers including atrial natriuretic peptide (ANP) and beta-myosin heavy chain (β-MHC). Additionally, TMAO treatment induced cardiac hypertrophy and cardiac fibrosis in SD rats. Reducing TMAO synthesis by antibiotics (Abs) attenuated TAC-induced cardiac hypertrophy and fibrosis. Furthermore, pharmacological inhibition of Smad3 by SIS3 significantly reduced the expression of ANP and β-MHC, and cardiomyocyte cell size in TMAO-treated group. These data for the first time demonstrate that gut microbe-derived metabolite TMAO induces cardiac hypertrophy and fibrosis involving Smad3 signaling, suggesting that inhibition of gut microbes or generation of TMAO may become a potential target for the prevention and treatment of cardiac hypertrophy.
Publisher
Elsevier Inc,Nature Publishing Group US,Nature Publishing Group
Subject
/ 14/34
/ 14/63
/ 631/80
/ 82/1
/ 82/80
/ 82/81
/ Animals
/ Aorta
/ Choline
/ Diet
/ Fibrosis
/ Gastrointestinal Microbiome - physiology
/ Heart
/ Male
/ Medicine
/ Methylamines - antagonists & inhibitors
/ Myocytes, Cardiac - drug effects
/ Myocytes, Cardiac - metabolism
/ Myocytes, Cardiac - pathology
/ Myosin
/ Rats
/ Rodents
/ Smad3 Protein - antagonists & inhibitors
